Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus BRINSUPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus BRINSUPRI.
AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE vs BRINSUPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone secretion.
BRINSUPRI is a novel oral cyclin-dependent kinase (CDK) inhibitor that selectively inhibits CDK4 and CDK6, thereby blocking phosphorylation of the retinoblastoma (Rb) protein and preventing G1-to-S phase cell cycle progression. This induces cell cycle arrest in cancer cells with intact Rb function.
Initial: 2.5-5 mg amlodipine / 10-20 mg benazepril orally once daily, titrated to 10/40 mg once daily based on response.
4 mg orally once daily, with or without food.
None Documented
None Documented
Amlodipine: 30-50 h (terminal), allowing once-daily dosing; benazeprilat: 10-11 h (terminal), effective for 24 h.
Terminal elimination half-life is approximately 20-30 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may extend to >50 hours, requiring dose adjustment.
Renal: Amlodipine 10% unchanged, benazeprilat (active metabolite) 50-60% in urine; biliary/fecal: amlodipine 20-25% as metabolites, benazeprilat 10-20% in feces.
Primarily renal excretion as unchanged drug (70-85%) and minor fecal elimination (10-15%). Biliary excretion accounts for <5%.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor